文献速递血脂与心血管预防

Omega-3脂肪酸治疗高甘油三酯血症:美国心脏协会科学声明

Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.
PubMed 文献 · Circulation · 2019-08-19

该科学声明总结了药理学剂量Omega-3脂肪酸(>3 g/d总EPA+DHA)对血脂和脂蛋白的影响。4 g/d EPA+DHA可使极高甘油三酯降低≥30%但升高LDL-C,而EPA单药不升高LDL-C;REDUCE-IT试验显示EPA单药使主要不良心血管事件减少25%。声明认为处方Omega-3脂肪酸(4 g/d)是降低甘油三酯的有效安全选择。

要点

  • 4 g/d EPA+DHA降低极高甘油三酯≥30%但升高LDL-C,EPA单药不升高LDL-C
  • EPA+DHA或EPA单药降低甘油三酯效果大致相当,单用或联合他汀均不升高LDL-C
  • REDUCE-IT试验支持4 g/d EPA单药用于他汀治疗高危患者以降低ASCVD风险

核心结论

  • 处方Omega-3脂肪酸(EPA+DHA或EPA单药)4 g/d是降低甘油三酯的有效安全选择,可单用或联合其他降脂药。

研究设计与样本

  • 美国心脏协会科学声明,基于新科学数据和Omega-3脂肪酸制剂的可及性,总结药理学剂量(>3 g/d总EPA+DHA)的脂质和脂蛋白效应。

主要发现

  • 4 g/d EPA+DHA治疗极高甘油三酯(≥500 mg/dL)降低甘油三酯≥30%,同时升高LDL-C;EPA单药不升高LDL-C。
  • 治疗高甘油三酯血症(200-499 mg/dL)时,EPA+DHA与EPA单药降低甘油三酯效果大致相当,单用或联合他汀均不升高LDL-C。
  • 最大规模4 g/d处方Omega-3脂肪酸试验中,非高密度脂蛋白胆固醇和载脂蛋白B适度降低,提示总致动脉粥样硬化脂蛋白减少。
  • REDUCE-IT随机安慰剂对照试验中,EPA单药使接受他汀治疗的高危患者主要不良心血管事件减少25%。
  • 4 g/d处方EPA+DHA治疗高甘油三酯血症的试验结果预计2020年公布。

关键数值与推荐

  • 高甘油三酯血症定义为甘油三酯200-499 mg/dL,极高甘油三酯定义为≥500 mg/dL。
  • 2002年美国心脏协会科学声明推荐Omega-3脂肪酸(EPA和DHA)2-4 g/d用于降低甘油三酯。
  • 药理学剂量定义为>3 g/d总EPA+DHA。
  • 处方Omega-3脂肪酸推荐剂量为4 g/d。

临床怎么用

  • 对于极高甘油三酯(≥500 mg/dL)患者,可选用4 g/d EPA+DHA或EPA单药降低甘油三酯,注意EPA+DHA可能升高LDL-C。
  • 对于高甘油三酯血症(200-499 mg/dL)患者,4 g/d EPA+DHA或EPA单药可单用或联合他汀降低甘油三酯。
  • 对于他汀治疗的高危患者,4 g/d EPA单药可考虑用于降低ASCVD风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hypertriglyceridemia (triglycerides 200-499 mg/dL) is relatively common in the United States, whereas more severe triglyceride elevations (very high triglycerides, ≥500 mg/dL) are far less frequently observed. Both are becoming increasingly prevalent in the United States and elsewhere, likely driven in large part by growing rates of obesity and diabetes mellitus. In a 2002 American Heart Association scientific statement, the omega-3 fatty acids (n-3 FAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) were recommended (at a dose of 2-4 g/d) for reducing triglycerides in patients with elevated triglycerides. Since 2002, prescription agents containing EPA+DHA or EPA alone have been approved by the US Food and Drug Administration for treating very high triglycerides; these agents are also widely used for hypertriglyceridemia. The purpose of this advisory is to summarize the lipid and lipoprotein effects resulting from pharmacological doses of n-3 FAs (>3 g/d total EPA+DHA) on the basis of new scientific data and availability of n-3 FA agents. In treatment of very high triglycerides with 4 g/d, EPA+DHA agents reduce triglycerides by ≥30% with concurrent increases in low-density lipoprotein cholesterol, whereas EPA-only did not raise low-density lipoprotein cholesterol in very high triglycerides. When used to treat hypertriglyceridemia, n-3 FAs with EPA+DHA or with EPA-only appear roughly comparable for triglyceride lowering and do not increase low-density lipoprotein cholesterol when used as monotherapy or in combination with a statin. In the largest trials of 4 g/d prescription n-3 FA, non-high-density lipoprotein cholesterol and apolipoprotein B were modestly decreased, indicating reductions in total atherogenic lipoproteins. The use of n-3 FA (4 g/d) for improving atherosclerotic cardiovascular disease risk in patients with hypertriglyceridemia is supported by a 25% reduction in major adverse cardiovascular events in REDUCE-IT (Reduction of Cardiovascular Events With EPA Intervention Trial), a randomized placebo-controlled trial of EPA-only in high-risk patients treated with a statin. The results of a trial of 4 g/d prescription EPA+DHA in hypertriglyceridemia are anticipated in 2020. We conclude that prescription n-3 FAs (EPA+DHA or EPA-only) at a dose of 4 g/d (>3 g/d total EPA+DHA) are an effective and safe option for reducing triglycerides as monotherapy or as an adjunct to other lipid-lowering agents.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation. 2019. PMID: 31422671. doi:10.1161/CIR.0000000000000709

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。